| Literature DB >> 30079761 |
Garyfalia Karponi1, Penelope-Georgia Papayanni1, Fani Zervou1, Asimina Bouinta2, Achilles Anagnostopoulos1,2, Evangelia Yannaki1,3.
Abstract
Stable gene marking and effective engraftment of gene-modified CD34+ hematopoietic stem cells is a prerequisite for gene therapy success but may be challenged by the inevitable cryopreservation of the final product prior to extensive quality assurance testing. We investigated the β-globin gene transfer potency in fresh and cryopreserved CD34+ cells from mobilized patients with β-thalassemia, as well as the qualitative impact of repeated freeze/thaw cycles on the functionality of cultured and unmanipulated CD34+ cells in terms of engrafting capacity in a xenotransplantation model, under partial myeloablation. Cells transduced fresh or after one freeze-thaw cycle yielded similar clonogenic and gene transfer frequencies. Repeated cryopreservation cycles did not affect the transduction rates whereas either one or two freeze-thaw cycles of cultured-but not of unmanipulated-cells significantly reduced their clonogenicity. No differences in the engrafting potential of gene-corrected cells subjected to either none or up to two cryopreservation cycles, were encountered post xenotransplantation. Overall, we assessed the gene transfer efficiency, clonogenicity and engrafting capacity of cryopreserved CD34+ cells and the impact of repeated freeze/thaw cycles in their performance. These observations may prove essential in the design of gene therapy trials, considerably facilitating their logistics.Entities:
Keywords: CD34+-cell processing; cryopreservation; engraftment; gene therapy; gene therapy trials; mobilization; thalassemia
Mesh:
Substances:
Year: 2018 PMID: 30079761 PMCID: PMC6206548 DOI: 10.1089/hgtb.2018.032
Source DB: PubMed Journal: Hum Gene Ther Methods ISSN: 1946-6536 Impact factor: 2.396